Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
CONCLUSIONS: Sacubitril/valsartan may provide superior benefits in reducing heart failure hospitalization rates, NT-proBNP levels, and improving NYHA classification in patients with HFpEF compared to ACEIs and ARBs. Sacubitril/valsartan might be considered as a preferred treatment option for HFpEF patients due to its benefits in reducing heart failure hospitalization rates and improving symptom severity.PMID:37917889 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - November 2, 2023 Category: Complementary Medicine Authors: Yanhong Mou Lijun Qin Lili Wang Yan Guo Xiaowei Zhang Jing Yu Source Type: research
Sacubitril/valsartan
(Source: Reactions Weekly)
Source: Reactions Weekly - November 1, 2023 Category: Drugs & Pharmacology Source Type: research
The short ‐term effects of sacubitril/valsartan therapy on myocardial oxygen consumption and energetic efficiency of cardiac work in heart failure with reduced ejection fraction. A randomized controlled study
ConclusionsWe found no differences in the energetic efficiency of cardiac work between ARNI and valsartan-only groups in HFrEF patients. However, ARNI appears to have hemodynamic and cardiac mechanical effects over valsartan in patients with HF. (EudraCT 2017-002113-64)This article is protected by copyright. All rights reserved. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - October 31, 2023 Category: Cardiology Authors: Sergey V. Nesterov,
Johanna R äty,
Wail Nammas,
Teemu Maaniitty,
Xavier Galloo,
Jan Stassen,
Sanna Laurila,
Tuija Vasankari,
Jenni Huusko,
Jeroen J Bax,
Antti Saraste,
Juhani Knuuti Tags: Research Article Source Type: research
Structured solubility behaviour in fed simulated intestinal fluids
This study has utilised nine bioequivalent simulated fed intestinal media recipes that cover over 90% of the compositional variability of sampled fed human intestinal fluid. The solubility of 24 drugs (Acidic; furosemide, ibuprofen, indomethacin, mefenamic acid, naproxen, phenytoin, piroxicam, valsartan, zafirlukast: Basic; aprepitant, atazanavir, bromocriptine, carvedilol, dipyridamole, posaconazole, tadalafil: Neutral; acyclovir, carbamazepine, felodipine, fenofibrate, griseofulvin, itraconazole, paracetamol, probucol) has been assessed to determine if structured solubility behaviour is present. The measured solubility b...
Source: European Journal of Pharmaceutics and Biopharmaceutics - October 27, 2023 Category: Drugs & Pharmacology Authors: Maria In ês Silva Ibrahim Khadra Kate Pyper Gavin W Halbert Source Type: research
Structured solubility behaviour in fed simulated intestinal fluids
This study has utilised nine bioequivalent simulated fed intestinal media recipes that cover over 90% of the compositional variability of sampled fed human intestinal fluid. The solubility of 24 drugs (Acidic; furosemide, ibuprofen, indomethacin, mefenamic acid, naproxen, phenytoin, piroxicam, valsartan, zafirlukast: Basic; aprepitant, atazanavir, bromocriptine, carvedilol, dipyridamole, posaconazole, tadalafil: Neutral; acyclovir, carbamazepine, felodipine, fenofibrate, griseofulvin, itraconazole, paracetamol, probucol) has been assessed to determine if structured solubility behaviour is present. The measured solubility b...
Source: European Journal of Pharmaceutics and Biopharmaceutics - October 27, 2023 Category: Drugs & Pharmacology Authors: Maria In ês Silva Ibrahim Khadra Kate Pyper Gavin W Halbert Source Type: research
Structured solubility behaviour in fed simulated intestinal fluids
This study has utilised nine bioequivalent simulated fed intestinal media recipes that cover over 90% of the compositional variability of sampled fed human intestinal fluid. The solubility of 24 drugs (Acidic; furosemide, ibuprofen, indomethacin, mefenamic acid, naproxen, phenytoin, piroxicam, valsartan, zafirlukast: Basic; aprepitant, atazanavir, bromocriptine, carvedilol, dipyridamole, posaconazole, tadalafil: Neutral; acyclovir, carbamazepine, felodipine, fenofibrate, griseofulvin, itraconazole, paracetamol, probucol) has been assessed to determine if structured solubility behaviour is present. The measured solubility b...
Source: European Journal of Pharmaceutics and Biopharmaceutics - October 27, 2023 Category: Drugs & Pharmacology Authors: Maria In ês Silva Ibrahim Khadra Kate Pyper Gavin W Halbert Source Type: research
Structured solubility behaviour in fed simulated intestinal fluids
This study has utilised nine bioequivalent simulated fed intestinal media recipes that cover over 90% of the compositional variability of sampled fed human intestinal fluid. The solubility of 24 drugs (Acidic; furosemide, ibuprofen, indomethacin, mefenamic acid, naproxen, phenytoin, piroxicam, valsartan, zafirlukast: Basic; aprepitant, atazanavir, bromocriptine, carvedilol, dipyridamole, posaconazole, tadalafil: Neutral; acyclovir, carbamazepine, felodipine, fenofibrate, griseofulvin, itraconazole, paracetamol, probucol) has been assessed to determine if structured solubility behaviour is present. The measured solubility b...
Source: European Journal of Pharmaceutics and Biopharmaceutics - October 27, 2023 Category: Drugs & Pharmacology Authors: Maria In ês Silva Ibrahim Khadra Kate Pyper Gavin W Halbert Source Type: research
Structured solubility behaviour in fed simulated intestinal fluids
This study has utilised nine bioequivalent simulated fed intestinal media recipes that cover over 90% of the compositional variability of sampled fed human intestinal fluid. The solubility of 24 drugs (Acidic; furosemide, ibuprofen, indomethacin, mefenamic acid, naproxen, phenytoin, piroxicam, valsartan, zafirlukast: Basic; aprepitant, atazanavir, bromocriptine, carvedilol, dipyridamole, posaconazole, tadalafil: Neutral; acyclovir, carbamazepine, felodipine, fenofibrate, griseofulvin, itraconazole, paracetamol, probucol) has been assessed to determine if structured solubility behaviour is present. The measured solubility b...
Source: European Journal of Pharmaceutics and Biopharmaceutics - October 27, 2023 Category: Drugs & Pharmacology Authors: Maria In ês Silva Ibrahim Khadra Kate Pyper Gavin W Halbert Source Type: research
Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model
AbstractHepatic impairment (HI) moderately (<5-fold) affects the systemic exposure (i.e., area under the plasma concentration –time curve [AUC]) of drugs that are substrates of the hepatic sinusoidal organic anion transporting polypeptide (OATP) transporters and are excreted unchanged in the bile and/or urine. However, the effect of HI on their AUC is much greater (>10-fold) for drugs that are also substrates of cytochrome P450 (CYP) 3A enzymes. Using the extended clearance model, through simulations, we identified the ratio of sinusoidal efflux clearance (CL) over the sum of metabolic and biliary CLs as important ...
Source: CPT: Pharmacometrics and Systems Pharmacology - October 20, 2023 Category: Drugs & Pharmacology Authors: Flavia Storelli,
Mayur K. Ladumor,
Xiaomin Liang,
Yurong Lai,
Paresh P. Chothe,
Osatohanmwen J. Enogieru,
Raymond Evers,
Jashvant D. Unadkat Tags: ARTICLE Source Type: research
Comparative analysis of sacubitril/valsartan and losartan potassium in the treatment of hypertension: efficacy, adverse reactions, and observations
CONCLUSION: For patients with hypertension, sacubitril/valsartan has a better treatment efficacy than losartan potassium, because it can effectively reduce blood pressure, the levels of inflammatory factors, and the rate of adverse reactions in patients.PMID:37854234 | PMC:PMC10579029 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - October 19, 2023 Category: Research Authors: Qunfei Ye Yanjun Sheng Xuan He Source Type: research
